课题基金 / 基金详情

Non-invasive molecular and morphological imaging of platelets and platelet targets

Non-invasive molecular and morphological imaging of platelets and platelet targets
血小板和血小板靶标的非侵入性分子和形态学成像
批准号:
208707095
负责人:
Professor Dr. Robert Feil
金额:
$0.0万
依托单位国家:
德国
项目类别:
Clinical Research Units
财政年份:
2011
资助国家:
德国
项目状态:
已结题
起止时间:
2010-12-31 至 2019-12-31

项目摘要

项目成果

Professor Dr. Robert Feil的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目旨在对活体中血小板和相关靶结构进行无创成像,并使用高分辨率扫描离子电导显微镜(SICM)在单细胞水平上对激活过程进行成像。本子项目的重点是创新成像,有3个重点:1)开发和验证用于疾病过程中血小板靶结构无创成像的分子标记,2)评估用于血小板PET无创成像的新型tk报告小鼠,以及3)应用高分辨率荧光- sicm成像单个活细胞的功能状态。对于研究小组内的不同合作伙伴,该子项目提供了一个小动物和临床翻译成像平台[正电子发射断层扫描(PET),光学成像(OI),磁共振断层扫描(MRT),计算机断层扫描(CT),联合成像(PET/MRT)和单个活细胞亚细胞结构的高分辨率显微镜(SICM)]。与财团内的不同合作伙伴相结合,这些技术将大大补充子项目。利用我们在放射标记、生物标志物和成像方法开发方面的专业知识,我们将可视化疾病过程中的血小板靶结构,以获得有关易感性、炎症和血管生成的信息。PET和MRT的结合在心血管医学中尤为重要,因为它可以精确地将放射性标记生物标志物的积累归因于形态结构,或者除了分子和解剖信息之外,还可以确定功能参数。此外,我们将开发一种新的转基因小鼠模型,结合PET,首次成像血栓细胞在健康和患病生物体中的生物分布和寿命。与非侵入性成像协同,荧光- sicm将在单细胞水平上提供血小板功能的信息。我们的实验室建立了所有必要的PET/MR成像方法。除[18F]FDG外,我们还将使用示踪剂对缺氧区域([18F]FMISO)或血管生成([64Cu]RGD)进行成像。特异性抗体将与螯合物dota结合,随后用64Cu进行放射性标记。长寿命的同位素也允许在体内追踪血小板或t细胞数天。血小板形成机制与血管生成和缺氧过程密切相关。现有的一系列方法构成了建立创新成像的基础,其依据是维和部队不同次级项目的主题优先次序。
英文摘要
This subprojects aims for non-invasive imaging of thrombocytes and relevant target structures in the living organism and using high-resolution scanning ion conductance microscopy (SICM) to image the process of activation on a single-cell level. The focus of this subproject is on innovative imaging with 3 priorities: 1) Development and validation of molecular markers for the non-invasive imaging of thrombocytic target structures in the process of disease, 2) evaluation of a new TK-reporter mouse for non-invasive imaging of thrombocytes with PET, and 3) application of highresolution fluorescence-SICM for the imaging of functional states in a single living cell. To the different cooperation partners within the research group this subproject offers a small animal and a clinical-translational imaging platform [positron-emission-tomography (PET), opticalimaging (OI), magnetic resonance tomography (MRT), computer tomography (CT), combined imaging (PET/MRT), and high-resolution microscopy (SICM) of sub-cellularstructures of a single living cell]. In combination with the different cooperation partners within the consortium these technologies will significantly complement the subprojects. Using our expertise in radiolabeling and in the development of biomarkers and imaging methods we will visualize thrombocytic target structures in the process of disease to gain information about vulnerability, inflammation, and angiogenesis. The combination of PET and MRT is especially important in cardiovascular medicine in order to precisely attribute the accumulation of a radiolabeled biomarker to a morphological structure or to allow the determination of functional parameters in addition to molecular and anatomical information. Further, we will develop a new transgenic mouse model in combination with PET to image,for the first time,the biodistribution and lifespan of thrombocytes in the healthy and diseased organism. Synergisticallyto non-invasive imaging, fluorescence-SICM will give information about thrombocyte function on the level of single cells. All necessary methods for PET/MR imaging are established in our laboratory. Next to [18F]FDG we will also use tracers for imaging hypoxic areas ([18F]FMISO) or angiogenesis ([64Cu]RGD). Specific antibodies will be conjugated with the chelatorDOTA and will subsequently be radiolabeled with 64Cu. Long-lived isotopes also allow in vivo-tracking of thrombocytes or T-cells for several days.Thrombocytic mechanisms are closely connected to angiogenetic and hypoxic processes. The existing spectrum of methods forms the basis for the establishment of innovative imaging, based on the thematic priorities of the different KFO-subprojects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Real-time analysis of cGMP signals in platelets in vitro and in vivo
Global and local cGMP signals in growth control
Coordination Funds
Modulation von vaskulärer Plastizität und Gefäßkrankheiten durch die cGMP-Signaltransduktion
国内基金
海外基金
基于深穿透拉曼光谱的安全光照剂量的深层病灶无创检测与深度预测
  • 批准号:
    82372016
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    林俐
  • 依托单位: